New Medical Supplies for Ukraine's Defense

Ukraine has procured 12,000 doses of the PLX-R18 medication, intended for treating radiation sickness (acute radiation syndrome), from the Israeli biotechnology firm Pluri. This purchase is made as a precaution against potential nuclear threats.

This was announced by Israel's ambassador to Ukraine, Michael Brodsky, on Telegram, referencing The Times of Israel.

Reserve for nuclear threats: Ukraine has acquired PLX-R18 medication

The ambassador quoted the Israeli publication, noting that “the Israeli company Pluri has signed a contract with a Ukrainian cord blood bank for the supply of PLX-R18.” This medication assists in the recovery of platelets as well as red and white blood cells damaged by radiation exposure.

Overall, Ukraine will receive enough doses to treat 6,000 individuals. The purchased medication will be stored as a reserve in the event of a nuclear threat. If necessary, it will be quickly dispatched to hospitals across the country to assist the affected.

In March, Russian forces used chemical weapons against the Armed Forces of Ukraine nearly 770 times.

Earlier, the General Staff of the Armed Forces of Ukraine reported 767 instances of Russian troops using munitions containing hazardous chemicals against Ukraine's defense forces during March 2025.

Since February 2023, when such attacks became systematic, 7,730 similar cases have been recorded.

As of early March, since the beginning of the full-scale invasion of Ukraine, Russian troops have used munitions with toxic chemical compounds over 6,900 times.

In March 2024, the Ukrainian delegation at the OSCE urged the international community to respond, beyond mere political condemnation, to Russia's use of chemical weapons against Ukrainian defenders.